Volume | 302,704 |
|
|||||
News | - | ||||||
Day High | 1.21 | Low High |
|||||
Day Low | 1.12 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Clearside Biomedical Inc | CLSD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.17 | 1.12 | 1.21 | 1.12 | 1.18 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
1,110 | 302,704 | US$ 1.16 | US$ 352,134 | - | 0.650101 - 2.12 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
16:10:59 | 59 | US$ 1.15 | USD |
Clearside Biomedical Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
84.43M | 74.72M | - | 8.23M | -32.49M | -0.43 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Clearside Biomedical News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CLSD Price Data
Period †| Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.19 | 1.28 | 1.12 | 1.21 | 119,932 | -0.07 | -5.88% |
1 Month | 1.33 | 1.52 | 1.12 | 1.33 | 191,590 | -0.21 | -15.79% |
3 Months | 1.71 | 1.76 | 1.10 | 1.35 | 221,742 | -0.59 | -34.50% |
6 Months | 0.9999 | 2.12 | 0.99 | 1.46 | 280,730 | 0.1201 | 12.01% |
1 Year | 1.52 | 2.12 | 0.650101 | 1.31 | 206,122 | -0.40 | -26.32% |
3 Years | 4.33 | 7.73 | 0.650101 | 2.95 | 378,642 | -3.21 | -74.13% |
5 Years | 1.04 | 7.73 | 0.56 | 2.84 | 581,207 | 0.08 | 7.69% |
Clearside Biomedical Description
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision. |